Summit Therapeutics Inc.

SMMT

$13.03B

Large Cap

NASDAQBiotechnology🇺🇸North America159 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Nov 1, 2026

38w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date ivonescimab

November 2026~

Extracted from: Summit gets November PDUFA date for its PD-1xVEGF bispecific

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

AK112 Injection

Phase 3

Non-Squamous Non-small Cell Lung Cancer

Ridinilazole

Phase 3

Clostridioides Difficile Infection

Drug: Ivonescimab Injection

Phase 3

Metastatic Colorectal Cancer (CRC)

Pembrolizumab Injection

Phase 3

Non-Small Cell Lung Cancer

Ivonescimab Injection

Phase 3

Non-Small Cell Lung Cancer

Fidaxomicin

Phase 2

Clostridium Difficile Infection

SMT19969

Phase 2

Clostridium Difficile Infection

Drug Name	Phase	Indication	Designations
AK112 Injection	Phase 3	Non-Squamous Non-small Cell Lung Cancer	-
Ridinilazole	Phase 3	Clostridioides Difficile Infection	-
Drug: Ivonescimab Injection	Phase 3	Metastatic Colorectal Cancer (CRC)	-
Pembrolizumab Injection	Phase 3	Non-Small Cell Lung Cancer	-
Ivonescimab Injection	Phase 3	Non-Small Cell Lung Cancer	-
Fidaxomicin	Phase 2	Clostridium Difficile Infection	-
SMT19969	Phase 2	Clostridium Difficile Infection	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

SMMT News